Orion PharmaDHA:ORIONPHARM 71 Buyback Yield % is 0.00 as of Jul. 06, 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 71/100 and a GF Value™ of BDT20.26 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 125 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 799999.2% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Orion Pharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Buyback Yield % Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Buyback Yield % vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a Buyback Yield % of 0.00 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #999999 out of 125 companies in the Utilities - Independent Power Producers industry.
Is Orion Pharma's Buyback Yield % too high?
Orion Pharma's current Buyback Yield % is 0.00. Based on the distribution chart, Orion Pharma ranks #999999 out of 125 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Buyback Yield % compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #999999 out of 125 companies for Buyback Yield %. This places Orion Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for an Utilities - Independent Power Producers company?
A good Buyback Yield % depends on the Utilities - Independent Power Producers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Orion Pharma and its competitors. Orion Pharma's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.26, compared to a current price of BDT28.30 — trading 39.7% above its estimated fair value. The current Buyback Yield % is 0.00. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Buyback Yield % is 0.00 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.30 is trading 39.7% above its estimated GF Value™ of BDT20.26.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Buyback Yield %: 0.00
GF Value™: BDT20.26 vs. price of BDT28.30 (39.7% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score
Get the complete analysis for DHA:ORIONPHARM
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
